Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Stephen R, Marcello"'
Autor:
Peter Zimetbaum, Robert N. D'Angelo, Robert W. Yeh, Laura Goldstein, Patricia Tung, Motiur Rahman, Iftekhar Kalsekar, Stephen R. Marcello, Rahul Khanna
Publikováno v:
Journal of the American College of Cardiology. 75:410
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf76bf974725a41190cd2fe76a6a4717
https://doi.org/10.1016/s0735-1097(20)31037-8
https://doi.org/10.1016/s0735-1097(20)31037-8
Autor:
Peter J. Schwartz, Steven N. Singh, Craig M. Pratt, A. John Camm, Stephen R. Marcello, Alive Investigators, Michael J. Holroyde, Hussein R. Al-Khalidi, Jose Brum
Publikováno v:
Journal of the American College of Cardiology. 43:1211-1216
Objectives The purpose of this study was to assess the effect of oral azimilide dihydrochloride (AZ) 100 mg versus placebo on the onset, termination, and prevalence of atrial fibrillation (AF) in a subpopulation of patients in the Azimilide Postinfar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3799f8250bb5cc28d334cee269ba4e7a
https://doi.org/10.1016/j.jacc.2003.10.057
https://doi.org/10.1016/j.jacc.2003.10.057
Autor:
Stuart J. Connolly, William E. Wilkinson, Stephen R. Marcello, Edward L.C. Pritchett, Richard L. Page, Daniel J. Schnell
Publikováno v:
American Heart Journal. 143:643-649
Background Azimilide is a novel classification III antiarrhythmic agent that blocks both IKrand IKsand shows evidence of efficacy in patients with atrial fibrillation or flutter. Its effect on paroxysmal supraventricular tachycardia (PSVT) has not be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06b6f8d87d9054422fce19d1bc83c86e
https://doi.org/10.1067/mhj.2002.120969
https://doi.org/10.1067/mhj.2002.120969
Autor:
Stephen R. Marcello, Stuart J. Connolly, Daniel J. Schnell, Marcia C. Schulte, Edward L.C. Pritchett, Richard L. Page, William E. Wilkinson
Publikováno v:
Journal of Clinical Pharmacology. 42:388-394
The purpose of this study was to assess the effect of azimilide, a Class III antiarrhythmic drug, on ECG conduction intervals recorded during sinus rhythm in patients with a history of symptomatic atrial fibrillation or atrial flutter. In Phase I cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f43928b9edae7c204fbc6b425922679
https://doi.org/10.1177/0091270002424004
https://doi.org/10.1177/0091270002424004
Autor:
Stephen R. Marcello, Edward L.C. Pritchett, William E. Wilkinson, Richard L. Page, Stuart J. Connolly, Daniel J. Schnell
Publikováno v:
The American Journal of Cardiology. 88:974-979
We evaluated the efficacy and safety of azimilide, a new class III antiarrhythmic agent that blocks both the slow and fast components of the cardiac-delayed rectifier potassium currents in 4 randomized, double-blind, placebo-controlled trials with si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197142a483dc6f802a2c5a173b665036
https://doi.org/10.1016/s0002-9149(01)01973-7
https://doi.org/10.1016/s0002-9149(01)01973-7
Autor:
Stuart J. Connolly, Daniel J. Schnell, Stephen R. Marcello, William E. Wilkinson, Edward L.C. Pritchett, Richard L. Page
Publikováno v:
Journal of the American College of Cardiology. 36(3):794-802
OBJECTIVES The purpose of this study was to assess the effectiveness of azimilide, a class III antiarrhythmic drug, in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation, atrial flutter or both. BACKGROU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbafd490b0a3b26d3bc749c00bb93d97
Autor:
Alfred E. Corey, Nikhil Parekh, Stephen R. Marcello, Christopher Brezovic, Roger Karam, Hussein R. Al-Khalidi, Kevin Douglas Taylor
Publikováno v:
Biopharmaceutics & Drug Disposition. 20:59-68
This study assessed steady-state azimilide pharmacokinetics and pharmacodynamics in 119 healthy male and female volunteers. Parallel groups of 18-40-year-old subjects received doses of 35, 100, 150 or 200 mg day(-1) for up to 14 days, with 1, 2 or 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38eb46f2785d7f1ce1ecdfb8de36c042
https://doi.org/10.1002/(sici)1099-081x(199903)20:2<59::aid-bdd155>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199903)20:2<59::aid-bdd155>3.0.co
Publikováno v:
The American Journal of Cardiology. 81:40D-46D
Azimilide, a novel class III antiarrhythmic agent, blocks both the slowly activating (IKs) and rapidly activating (IKr) components of the delayed rectifier potassium current, which distinguishes it from conventional potassium channel blockers such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f13951129a9d904bc1fa5254b1baed
https://doi.org/10.1016/s0002-9149(98)00152-0
https://doi.org/10.1016/s0002-9149(98)00152-0
Autor:
Stephen R. Marcello, Peter J. Schwartz, Jose Brum, Martin Borggrefe, Paul Dorian, Michael J. Holroyde, Hussein R. Al-Khalidi, A. John Camm, Craig M. Pratt
Publikováno v:
Journal of the American College of Cardiology. 48(3)
Objectives The purpose of this study was to assess the incidence, temporal characteristics, and risk factors associated with azimilide-associated torsades de pointes (TdP) ventricular tachycardia. Background Azimilide dihydrochloride is a class III a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729aedbbbf49294d8d52ab61231cba88
https://pubmed.ncbi.nlm.nih.gov/16875971
https://pubmed.ncbi.nlm.nih.gov/16875971
Publikováno v:
Cardiac electrophysiology review. 7(3)
Azimilide dihydrochloride (or azimilide) is a class III antiarrhythmic drug currently under investigation that has been tested in atrial fibrillation in four randomized, placebo-controlled clinical trials to assess efficacy and dose range. These inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0081490c0bacfe1bdae2343bd366b77
https://pubmed.ncbi.nlm.nih.gov/14739716
https://pubmed.ncbi.nlm.nih.gov/14739716